Blanquerna Faculty of Health Sciences, Ramon Llull University, Spain
*Corresponding author:Conxita Mestres Miralles, Blanquerna Faculty of Health Sciences, Ramon Llull University, Spain, Tel: 934232180; Email: email@example.com
Submission: September 08, 2017; Published: September 19, 2017
Volume1 Issue1 September 2017
an increase of drug adverse effects, hospitalizations and length of stay, morbidity and mortality. There is a great awareness of this problem and much workhas been done in order to reduce the polypharmacy and improve the quality of the drug prescription in these patients. With this aim, we have different tools and initiatives, being the STOP-START and Beers Criteria those upstanding. However, it is not easy to implement those criteria or to do perform other measures when confronted with complex treatments. Comorbidityand constant worsening of the pathologies in these patients makes very difficult to reduce in the long runthe number of drugs that they have to take.